Post by Cirrus Therapeutics

Geographic atrophy is the advanced, late stage of dry age-related macular degeneration, but too often it is discussed only in clinical terms rather than as the progressive loss of central vision that changes how people read, recognize faces, and move through daily life. As GA advances, areas of the retina are permanently lost, creating blind spots that can slowly enlarge over time and take away independence with them. At Cirrus Therapeutics, we believe understanding the biology of this disease matters. GA does not appear overnight. It emerges through the gradual breakdown of the macula, with damage that builds over time until retinal cells are lost. That is why our focus is on upstream biology, including the immune dysregulation that can set this process in motion long before damage becomes irreversible. “Geographic atrophy is a powerful reminder that dry AMD is not a benign disease of aging. It is progressive, biologically complex, and deeply consequential for patients,” said Andrew Dick, MD, Co-founder and Chief Scientific Advisor. “We are working to intervene earlier and more fundamentally, with the goal of protecting retinal cells before central vision is permanently lost.” We created this video to make GA easier to understand and to highlight why better solutions are urgently needed. Watch below to learn more about how geographic atrophy develops and how Cirrus is approaching dry AMD through ocular immunology and IRAK-M–targeted gene therapy. #vision #AMD #DryAMD #WetAMD #optometry #opthalmology #healthcare #science #STEM #biotech #biopharma #research #lifesciences #geographicatrophy #GA

Video Content